Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.
Energy & Infrastructure Analyst Lewis and Fixed Income Strategist Malley discuss bitcoin mining trends and themes across the capital ...
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback